Hostname: page-component-89b8bd64d-ksp62 Total loading time: 0 Render date: 2026-05-09T07:34:52.524Z Has data issue: false hasContentIssue false

Human bioavailability of phenolic compounds found in common beans: the use of high-resolution MS to evaluate inter-individual variability

Published online by Cambridge University Press:  08 November 2019

Elsa Mecha
Affiliation:
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras2780-157, Portugal
Rodrigo P. Feliciano
Affiliation:
Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University of Düsseldorf, DüsseldorfD-40225, Germany
Ana Rodriguez-Mateos
Affiliation:
Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University of Düsseldorf, DüsseldorfD-40225, Germany Department of Nutritional Sciences, School of Life Course Sciences, King’s College London, LondonSE1 9NH, UK
Sandra D. Silva
Affiliation:
iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras2781-901, Portugal
Maria Eduardo Figueira
Affiliation:
iMed. Ulisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisboa1649-003, Portugal
Maria Carlota Vaz Patto
Affiliation:
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras2780-157, Portugal
Maria Rosário Bronze*
Affiliation:
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras2780-157, Portugal iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras2781-901, Portugal iMed. Ulisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisboa1649-003, Portugal
*
*Corresponding author: Maria Rosário Bronze, email mbronze@ibet.pt
Rights & Permissions [Opens in a new window]

Abstract

Although common beans (Phaseolus vulgaris L.) are consumed worldwide, studies on the metabolic fate of phenolic compounds from common beans are still very scarce. The present work aimed to study the bioavailability of phenolic compounds in human plasma and urine, after acute consumption of a single meal of cooked common beans. Blood and urine of seven volunteers were collected before (0 h) and at different time points (1, 2, 4, 6 and 8 h for plasma and 0–2, 2–4, 4–6, 6–8 and 8–24 h for urine) after beans’ intake. Ultra-high performance liquid chromatography-quadrupole-time of flight-MS (UPLC-Q-TOF-MS) was used for quantification. After beans’ intake, 405 (sd 3) g, containing 188 mg of phenolic compounds (expressed as gallic acid equivalents), there was a significant increase (P < 0·05) in the plasma concentration of six metabolites and in the urinary excretion of eleven metabolites. After 1 h post-consumption, metabolites, such as kaempferol-3-O-glucuronide, showed a significant increase in plasma concentration, suggesting kaempferol’s glucuronidation in the upper gastrointestinal tract. More than 50 % of the total amount of metabolites, such as 4-methylcatechol-O-sulphate and dihydrocaffeic acid-3-O-sulphate, were excreted after 8 h post-consumption, indicating colonic bacterial metabolism of the phenolic compounds. Partial least square-discriminant analysis models clearly showed clusters of metabolites, which contributed to extend the list of compounds related to cooked common beans’ human intake at different time points and showed the human inter-individual variability in plasma concentration as well as in urinary excreted metabolites, after cooked common beans’ intake.

Information

Type
Full Papers
Copyright
© The Authors 2019 
Figure 0

Fig. 1. Study design scheme. After a diet free of phenolic compounds for 48 h, plasma (P) and urine (U) were collected at different time points, after a single meal of cooked common beans (404·7 (sd 2·7) g). , Controlled diet, free of phenolic compounds; , meal; , plasma (P)/urine (U) collection.

Figure 1

Table 1. Comparison of the moisture content and the total phenolic content (TPC) determined in traditional Portuguese common bean varieties (Averages and standard deviations)

Figure 2

Table 2. Phenolic composition of raw and corresponding cooked common beans by ultra-high performance liquid chromatography-quadrupole-time of flight-MS (UPLC-Q-TOF-MS): comparison with the published data

Figure 3

Table 3. Concentration (nm) of phenolic compounds and their metabolites in plasma, before (0 h) and after (1, 2, 4, 6 and 8 h) beans’ consumption, considering n 7 (Average values with their standard errors; CV %)

Figure 4

Table 4. Urinary excretion (amount in µg) of phenolic compounds metabolites determined at different time points* (Average values with their standard errors; CV %)

Figure 5

Fig. 2. Plasma pharmacokinetic and/or urinary excretion profiles of metabolites related to cooked common beans’ intake. Data are means (n 7), with standard errors represented by vertical bars. , Plasma (P); , urine (U).

Figure 6

Fig. 3. Variability of total urinary excretion (averages and standard deviations, in µg) of the phenolic compounds and their metabolites at different time points, before (0 h) and after common beans’ intake (0–2, 2–4, 4–6, 6–8 and 8–24 h), n 7.

Figure 7

Fig. 4. Principal component analysis (PCA) of the plasma samples collected before (0 h) and after common beans’ intake. (a) Loading plot of plasma metabolites (PC1 v. PC2), MP1, two-step_1-methylpyrogallol-O-sulphate; MP2, two-step_vanillic acid-4-O-sulphate; MP3, two-step_dihydroferulic acid-4-O-β-d-glucuronide; MP4, p-hydroxybenzaldehyde; MP5, 4-hydroxyhippuric acid; MP6, 3-hydroxyhippuric acid; MP7, hippuric acid; MP8, caffeic acid; MP9, m-coumaric acid; MP10, log_ferulic acid-4-O-glucuronide; MP11, log_kaempferol-3-O-glucuronide; MP12, Inverse_ferulic acid-4-O-sulphate. (b) Score plot of the plasma samples distributed in a space defined by the first two principal components (PC1 v. PC2). The label attributed to the plasma (P) included a first number, which defined the anonymous identification of each volunteer and after the underscore character the collection time period, meaning, for example, in the label P1_0, the plasma sample of volunteer 1 collected in the fasting period (0 h).

Figure 8

Fig. 5. Partial least square-discriminant analysis (PLS-DA) highlighting the plasma samples’ clustering. (a) Correlation loading plot of plasma metabolites, MP2, two step_vanillic acid-4-O-sulphate; MP5, 4-hydroxyhippuric acid; MP6, 3-hydroxyhippuric acid; MP8, caffeic acid; MP9, m-coumaric acid; MP10, log_ferulic acid-4-O-glucuronide; MP11, log_kaempferol-3-O-glucuronide; MP12, inverse_ferulic acid-4-O-sulphate. (b) Score plot of plasma samples distributed in the two first factors (▪, cluster 1; •, cluster 2; ▴, cluster 3). (c) Quality parameters of the PLS-DA model defined for the plasma samples. The samples’ identification was the same of Fig. 4.

Figure 9

Table 5. Plasma concentration of different metabolites (nm) in the described clusters (Averages and standard deviations)

Figure 10

Fig. 6. Principal component analysis (PCA) of the urine samples collected before (0 h) and after common beans’ consumption. (a) Loading plot of the urinary excreted metabolites (PC1 v. PC2), MU1, log_pyrogallol-1-O-sulphate; MU2, log_pyrogallol-2-O-sulphate; MU3, log_1-methyl pyrogallol-O-sulphate; MU4, log_protocatechuic acid; MU5, log_vanillic acid-4-O-sulphate; MU6, log_p-hydroxybenzoic acid; MU7, Inverse_m-hydroxybenzoic acid; MU8, log_o-hydroxybenzoic acid; MU9, log_catechol-O-sulphate; MU10, log_4-methylcatechol-O-sulphate; MU11, log_4-hydroxyhippuric acid; MU12, log_3-hydroxyhippuric acid; MU13, hippuric acid; MU14, log_caffeic acid-4-O-β-d-glucuronide; MU15, log_ferulic acid-4-O-glucuronide; MU16, log_dihydrocaffeic acid 3-O-sulphate; MU17, log_caffeic acid-3-O-β-d-glucuronide; MU18, log_dihydroferulic acid-4-O-β-d-glucuronide; MU19, log_caffeic acid; MU20, squared root_dihydroferulic acid-4-O-sulphate; MU21, log_ferulic acid-4-O-sulphate; MU22, log_dihydroisoferulic acid-3-O-β-d-glucuronide; MU23, log_sinapic acid; MU24, log_kaempferol-3-O-glucuronide. (b) Score plot of the urine samples in the space defined by the two first principal components (PC1 v. PC2). For the volunteer 1, the urine samples were not provided at 0–2 h and 6–8 h. The label attributed to the urine (U) samples included a first number, which defined the anonymous identification of each volunteer and after the underscore character the collection time period, meaning, for example, in the label U1_8–24, the urine sample of volunteer 1 collected in the time period 8–24 h after common beans’ intake.

Figure 11

Fig. 7. Partial least square-discriminant analysis (PLS_DA) highlighting the urine samples’ clustering. (a) Correlation loading plot of some selected urinary metabolites excreted during the study period, MU5, log_vanillic-4-O-sulphate; MU7, inverse_m-hydroxybenzoic acid; MU9, log_catechol-O-sulphate; MU10, 4-methylcatechol-O-sulphate; MU11, log_4-hydroxyhippuric acid; MU12, log_3-hydroxyhippuric acid; MU16, log_dihydrocaffeic acid-3-O-sulphate; MU17, log_caffeic acid-3-O-β-d-glucuronide; MU19, log_caffeic acid; MU23, log_sinapic acid; MU24, log_kaempferol-3-O-glucuronide. (b) Score plot of urine samples distributed along the two first factors (▪, cluster 1; •, cluster 2; ▴, cluster 3). For the volunteer 1, the urine samples were not provided at 0–2 h and 6–8 h. (c) Quality parameters of the PLS-DA model defined for the urine samples. The samples’ identification was the same of Fig. 6.

Figure 12

Table 6. Excreted amount of different metabolites (μg) in the described clusters (Averages and standard deviations)

Figure 13

Table 7. Summary of compounds quantified in raw and cooked Moleiro common bean extracts (CBE), plasma (P) and urine (U)

Figure 14

Fig. 8. Proposed metabolic pathways involved in human metabolism of phenolic compounds from common beans, based on previous literature(15,19,59). , Metabolites excreted in urine at a significant level; , metabolites with significant plasma concentrations; , metabolites with significant plasma concentrations and excreted amounts in urine; A, decarboxylation (phase I); B, dehydroxylation (phase I); C, dealkylation (phase I); D, O-methylation (phase II); E, O-sulfation (phase II); F, O-glucuronidation (phase II); G, reduction (phase I); H, oxidation of the C3 chain (phase I); I, fission of the C-ring (phase I); J, dimer’s cleavage (phase I); K, conjugation with glycine (phase II).

Supplementary material: File

Mecha et al. supplementary material

Tables S1-S6

Download Mecha et al. supplementary material(File)
File 312.9 KB